Association of a 40-Gene Expression Profile (40-GEP) with Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Benefit of Adjuvant Radiation Therapy (ART)
Main Article Content
Keywords
Adjuvant radiation therapy (ART), ART, 40-GEP, cSCC
Abstract
Purpose: Adjuvant radiation therapy (ART) is recommended based on high-risk clinicopathologic features of cutaneous squamous cell carcinoma (cSCC), but these criteria are wide-ranging, encompassing a broad range of patients. The 40-gene expression profile (40-GEP) test is a prognostic tool which classifies cSCC tumors into low (Class 1), moderate (Class 2A), and high (Class 2B) risk of metastasis. This study determined if the metastatic risk as assessed by 40-GEP in high-risk cSCC patients predicts benefit from ART.
Study: Samples were obtained from 920 patients who were matched on clinical risk factors and stratified by ART status, to create 49 matched patient strata. Randomly sampled pairs of matched ART and non-ART patients comprising 10,000 resampled cohorts were each analyzed for 5-year metastasis-free survival (nodal and/or distant events; MFS) and predicted time to metastatic event (using a standard ‘life expectancy’ algorithm).
Results: Median 5-year MFS rates for the resampled cohorts demonstrated a 50% improvement, on average, for Class 2B ART-treated patient cohorts compared to Class 2B non-ART-treated patient cohorts. Class 2B ART-treated patient cohorts showed a 5-fold delay in predicted time to metastatic event and a deceleration of disease progression as compared to non-ART-treated patients (Kolmogorov-Smirnov test, p<0.01), that was not observed for Class 1 or 2A patients (p>0.05 for each). No risk factor or staging system combined with ART status was able to identify groups that would benefit from ART treatment as well as the 40-GEP test.
Conclusions: The 40-GEP test identifies patients at highest risk of nodal or distant metastasis who are most likely to benefit from ART, as well as lower-risk cohorts who benefit less from ART. These findings provide greater specificity than current clinicopathologic guidelines on which to base decisions for ART.
References
2. Likhacheva A, Awan M, Barker CA, et al: Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 10:8–20, 2020
3. National Comprehensive Cancer Network: Squamous Cell Skin Cancer, NCCN Guidelines Version 1.2023, in NCCN Clinical Practice Guidelines in Oncology [Internet] https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf [Internet]Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
4. Wilmas KM, Nguyen Q-B, Patel J, et al: Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncology 17:4971–4982, 2021
5. Ruiz ES, Koyfman SA, Que SKT, et al: Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. J Am Acad Dermatol 82:420–429, 2020
6. Ibrahim SF, Kasprzak JM, Hall MA, et al: Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncol 18:833–847, 2022
7. Saleeby E, Bielinski K, Fitzgerald A, et al: A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC). J of Skin 6:482–496, 2022
8. Singh G, Tolkachjov SN, Farberg AS: Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm. Clin Cosmet Investig Dermatol 16:925–935, 2023
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.